CL2014001776A1 - Composicion farmaceutica topica que comprende: a) bexaroteno, b) al menos 1 corticosteroide y c) un portador o vehiculo; uso para el tratamiento o la prevencion de trastornos de la piel, como psoriasis. - Google Patents
Composicion farmaceutica topica que comprende: a) bexaroteno, b) al menos 1 corticosteroide y c) un portador o vehiculo; uso para el tratamiento o la prevencion de trastornos de la piel, como psoriasis.Info
- Publication number
- CL2014001776A1 CL2014001776A1 CL2014001776A CL2014001776A CL2014001776A1 CL 2014001776 A1 CL2014001776 A1 CL 2014001776A1 CL 2014001776 A CL2014001776 A CL 2014001776A CL 2014001776 A CL2014001776 A CL 2014001776A CL 2014001776 A1 CL2014001776 A1 CL 2014001776A1
- Authority
- CL
- Chile
- Prior art keywords
- bexarotene
- corticosteroid
- psoriasis
- prevention
- carrier
- Prior art date
Links
- 201000004681 Psoriasis Diseases 0.000 title 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 title 1
- 229960002938 bexarotene Drugs 0.000 title 1
- 239000003246 corticosteroid Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000017520 skin disease Diseases 0.000 title 1
- 239000012049 topical pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12000077.3A EP2612665A1 (en) | 2012-01-09 | 2012-01-09 | Topical pharmaceutical compositions comprising bexarotene and a corticosteroide |
US201261585786P | 2012-01-12 | 2012-01-12 | |
US201261598095P | 2012-02-13 | 2012-02-13 | |
EP12000909 | 2012-02-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014001776A1 true CL2014001776A1 (es) | 2014-08-29 |
Family
ID=48781060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014001776A CL2014001776A1 (es) | 2012-01-09 | 2014-07-02 | Composicion farmaceutica topica que comprende: a) bexaroteno, b) al menos 1 corticosteroide y c) un portador o vehiculo; uso para el tratamiento o la prevencion de trastornos de la piel, como psoriasis. |
Country Status (21)
Country | Link |
---|---|
US (1) | US20140349981A1 (es) |
EP (1) | EP2802321A1 (es) |
JP (1) | JP2015503573A (es) |
KR (1) | KR20140107370A (es) |
CN (1) | CN104053437A (es) |
AU (1) | AU2012365658A1 (es) |
BR (1) | BR112014015578A8 (es) |
CA (1) | CA2857207A1 (es) |
CL (1) | CL2014001776A1 (es) |
CO (1) | CO7000772A2 (es) |
CR (1) | CR20140326A (es) |
EA (1) | EA201400806A1 (es) |
GT (1) | GT201400146A (es) |
HK (1) | HK1198423A1 (es) |
IL (1) | IL232765A0 (es) |
MX (1) | MX2014007300A (es) |
PE (1) | PE20142375A1 (es) |
PH (1) | PH12014501573A1 (es) |
SG (1) | SG11201403762PA (es) |
WO (1) | WO2013104399A1 (es) |
ZA (1) | ZA201403483B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015026990A2 (en) | 2013-08-20 | 2015-02-26 | University Of Washington Through Its Center For Commercialization | Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydrolase |
JP6997624B2 (ja) | 2015-06-18 | 2022-01-17 | ボシュ ヘルス ユーエス,エルエルシー. | 乾癬を治療するためのコルチコステロイドおよびレチノイドを含む局所用組成物 |
US11311482B2 (en) | 2017-05-12 | 2022-04-26 | Bausch Health Us, Llc | Topical compositions and methods for treating skin diseases |
EP3856155A4 (en) * | 2018-09-28 | 2022-10-05 | Joel Studin | DELIVERY OF STEROIDS AND LARGE MOLECULES THROUGH THE PORE |
CN113164384A (zh) * | 2018-10-26 | 2021-07-23 | 维拉莫有限公司 | 黏膜粘附性凝胶组合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0969847A1 (en) | 1997-02-20 | 2000-01-12 | Allergan Sales, Inc. | Tazarotene and corticosteroid treatment for psoriasis |
CN1210034C (zh) * | 2002-12-06 | 2005-07-13 | 重庆华邦制药股份有限公司 | 治疗银屑病的药物组合物 |
CN1210035C (zh) | 2003-09-29 | 2005-07-13 | 中国医学科学院皮肤病研究所 | 治疗银屑病的复方外用药物 |
-
2012
- 2012-12-18 CN CN201280066556.XA patent/CN104053437A/zh active Pending
- 2012-12-18 US US14/371,045 patent/US20140349981A1/en not_active Abandoned
- 2012-12-18 EA EA201400806A patent/EA201400806A1/ru unknown
- 2012-12-18 PE PE2014000979A patent/PE20142375A1/es not_active Application Discontinuation
- 2012-12-18 WO PCT/EP2012/005237 patent/WO2013104399A1/en active Application Filing
- 2012-12-18 JP JP2014550646A patent/JP2015503573A/ja active Pending
- 2012-12-18 BR BR112014015578A patent/BR112014015578A8/pt not_active Application Discontinuation
- 2012-12-18 CA CA2857207A patent/CA2857207A1/en not_active Abandoned
- 2012-12-18 EP EP12816241.9A patent/EP2802321A1/en not_active Withdrawn
- 2012-12-18 MX MX2014007300A patent/MX2014007300A/es unknown
- 2012-12-18 KR KR1020147018455A patent/KR20140107370A/ko not_active Withdrawn
- 2012-12-18 SG SG11201403762PA patent/SG11201403762PA/en unknown
- 2012-12-18 HK HK14111918.0A patent/HK1198423A1/xx unknown
- 2012-12-18 AU AU2012365658A patent/AU2012365658A1/en not_active Abandoned
-
2014
- 2014-05-14 ZA ZA2014/03483A patent/ZA201403483B/en unknown
- 2014-05-22 IL IL232765A patent/IL232765A0/en unknown
- 2014-06-27 CO CO14139629A patent/CO7000772A2/es unknown
- 2014-07-02 CL CL2014001776A patent/CL2014001776A1/es unknown
- 2014-07-08 PH PH12014501573A patent/PH12014501573A1/en unknown
- 2014-07-08 CR CR20140326A patent/CR20140326A/es unknown
- 2014-07-09 GT GT201400146A patent/GT201400146A/es unknown
Also Published As
Publication number | Publication date |
---|---|
PH12014501573A1 (en) | 2014-10-08 |
MX2014007300A (es) | 2014-07-28 |
CR20140326A (es) | 2015-01-16 |
AU2012365658A1 (en) | 2014-07-03 |
PE20142375A1 (es) | 2015-01-11 |
IL232765A0 (en) | 2014-07-31 |
EP2802321A1 (en) | 2014-11-19 |
BR112014015578A2 (pt) | 2017-06-13 |
ZA201403483B (en) | 2015-06-24 |
SG11201403762PA (en) | 2014-07-30 |
CN104053437A (zh) | 2014-09-17 |
HK1198423A1 (en) | 2015-04-24 |
JP2015503573A (ja) | 2015-02-02 |
CO7000772A2 (es) | 2014-07-21 |
KR20140107370A (ko) | 2014-09-04 |
US20140349981A1 (en) | 2014-11-27 |
WO2013104399A1 (en) | 2013-07-18 |
GT201400146A (es) | 2015-10-12 |
BR112014015578A8 (pt) | 2017-07-04 |
EA201400806A1 (ru) | 2015-02-27 |
CA2857207A1 (en) | 2013-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
CO2017011851A2 (es) | Compuestos novedosos | |
CL2014003388A1 (es) | Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades. | |
CL2014000806A1 (es) | Compuestos derivados de 1-arilcarbonil-4-oxi-piperidino; composicion farmaceutica que los comprende; uso para la prevencion o el tratamiento de enfermedades neurodegenerativas tales como enfermedad de alzheimer, enfermedad de parkinson, enfermedad de huntington o esclerosis multiple. | |
CL2012002606A1 (es) | Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales. | |
GT201300209A (es) | Compuestos y composiciones como inhibidores de la trk | |
CL2015001358A1 (es) | Potenciadores del cftr deuterados | |
CL2014002334A1 (es) | Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras. | |
MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
ECSP12012310A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
UY35391A (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c | |
CA2894892A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
CL2014001838A1 (es) | Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras. | |
DOP2016000253A (es) | Nuevos compuestos | |
UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
MX376183B (es) | Composiciones para el tratamiento de rosacea. | |
CL2014001776A1 (es) | Composicion farmaceutica topica que comprende: a) bexaroteno, b) al menos 1 corticosteroide y c) un portador o vehiculo; uso para el tratamiento o la prevencion de trastornos de la piel, como psoriasis. | |
GT201400161A (es) | Fenilimidazopirazoles sustituidos y su uso | |
PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
CL2014002845A1 (es) | Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2. | |
CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. |